GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (NYSE:COR) » Definitions » ROC %

COR (Cencora) ROC % : 0.86% (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Cencora ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Cencora's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was 0.86%.

As of today (2024-12-14), Cencora's WACC % is 8.36%. Cencora's ROC % is 11.78% (calculated using TTM income statement data). Cencora generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Cencora ROC % Historical Data

The historical data trend for Cencora's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cencora ROC % Chart

Cencora Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.41 12.86 11.34 11.20 11.86

Cencora Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.80 12.06 15.37 11.49 0.86

Cencora ROC % Calculation

Cencora's annualized Return on Capital (ROC %) for the fiscal year that ended in Sep. 2024 is calculated as:

ROC % (A: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Sep. 2023 ) + Invested Capital (A: Sep. 2024 ))/ count )
=3156.949 * ( 1 - 24.19% )/( (20401.264 + 19960.185)/ 2 )
=2393.2830369/20180.7245
=11.86 %

where

Invested Capital(A: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=62558.746 - 48189.854 - ( 2592.051 - max(0, 48831.198 - 42798.826+2592.051))
=20401.264

Invested Capital(A: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=67101.667 - 53700.722 - ( 3132.648 - max(0, 54277.053 - 47717.813+3132.648))
=19960.185

Cencora's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=2900.12 * ( 1 - 94.04% )/( (20030.269 + 19960.185)/ 2 )
=172.847152/19995.227
=0.86 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=66772.423 - 52408.759 - ( 3306.2 - max(0, 52973.867 - 47307.262+3306.2))
=20030.269

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=67101.667 - 53700.722 - ( 3132.648 - max(0, 54277.053 - 47717.813+3132.648))
=19960.185

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cencora  (NYSE:COR) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cencora's WACC % is 8.36%. Cencora's ROC % is 11.78% (calculated using TTM income statement data). Cencora generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cencora ROC % Related Terms

Thank you for viewing the detailed overview of Cencora's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cencora Business Description

Address
1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Executives
Lazarus Krikorian officer: Senior Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Steven H Collis officer: President & CEO 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Silvana Battaglia officer: Executive Vice President 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Walgreens Boots Alliance, Inc. 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Gina Clark officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Dermot Mark Durcan director
Robert P. Mauch officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Elizabeth S Campbell officer: Executive Vice President 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Leslie E Donato officer: EVP & Chief Strategy Officer 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Werner Baumann director 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Lauren M Tyler director C/O ALLEGHANY CORPORATION, 1411 BROADWAY, 34TH FLOOR, NEW YORK NY 10018
Redonda Miller director 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Lorence H. Kim director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Walgreens Boots Alliance Holdings Llc 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Lon R Greenberg director 460 NORTH GULPH ROAD, KING OF PRUSSIA PA 19406